Analysis of hormone antagonists in clinical and municipal wastewater by isotopic dilution liquid chromatography tandem mass spectrometry

AbstractA comprehensive method was developed for the simultaneous trace analysis of ten hormone antagonist pharmaceuticals (raloxifene, exemestane, letrozole, anastrozole, mifepristone, finastride, tamoxifen, N-desmethyltamoxifen, clomiphene, and toremifene) in municipal sewage and hospital wastewater samples. The target compounds were firstly extracted using an Oasis HLB cartridge, followed by purification by an aminopropyl cartridge, and were then analyzed by liquid chromatography electrospray ionization tandem mass spectrometry in positive ion mode. The recoveries for the analytes based on internal standard calibration in different test matrices ranged from 67.6 to 118.6% (with the exception of mifepristone in clinical wastewater samples), with relative standard deviations less than 20%. The method quantification limits of the ten pharmaceuticals were in the range 0.10–2.0 ng/L. Excluding exemestane and N-desmethyltamoxifen, eight drugs were detected at 0.20–195.0 ng/L in hospital wastewater and municipal wastewater samples from Beijing. FigureAnalysis of hormone antagonists in clinical and municipal wastewater by liquid chromatography tandem mass spectrometry

[1]  K. Thomas,et al.  Determination of selected human pharmaceutical compounds in effluent and surface water samples by high-performance liquid chromatography-electrospray tandem mass spectrometry. , 2003, Journal of chromatography. A.

[2]  Jianying Hu,et al.  Trace analysis of androgens and progestogens in environmental waters by ultra-performance liquid chromatography-electrospray tandem mass spectrometry. , 2008, Journal of chromatography. A.

[3]  John L. Zhou,et al.  Simultaneous determination of endocrine disrupting phenolic compounds and steroids in water by solid-phase extraction-gas chromatography-mass spectrometry. , 2004, Journal of chromatography. A.

[4]  Damià Barceló,et al.  Comparative study of an estradiol enzyme-linked immunosorbent assay kit, liquid chromatography-tandem mass spectrometry, and ultra performance liquid chromatography-quadrupole time of flight mass spectrometry for part-per-trillion analysis of estrogens in water samples. , 2007, Journal of chromatography. A.

[5]  I. White.  Anti-oestrogenic drugs and endometrial cancers. , 2001, Toxicology letters.

[6]  A. D. Schryver,et al.  Systemic treatment of early breast-cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31000 recurrences and 24000 deaths among 75000 women: 1 , 1992 .

[7]  P. Taylor.  Matrix effects: the Achilles heel of quantitative high-performance liquid chromatography-electrospray-tandem mass spectrometry. , 2005, Clinical biochemistry.

[8]  Zijian Wang,et al.  Tamoxifen effects on the early life stages and reproduction of Japanese medaka (Oryzias latipes). , 2007, Environmental toxicology and pharmacology.

[9]  Shuo Wang,et al.  Analysis of steroidal estrogen residues in food and environmental samples , 2008 .

[10]  D. Baird,et al.  Mifepristone-induced amenorrhoea is associated with an increase in microvessel density and glucocorticoid receptor and a decrease in stromal vascular endothelial growth factor. , 2006, Human reproduction.

[11]  B. Matuszewski,et al.  Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. , 2003, Analytical chemistry.

[12]  J. Willem,et al.  Risk of endometrial cancer after tamoxifen treatment of breast cancer , 1994, The Lancet.

[13]  H. Rosenkranz,et al.  A study of the structural basis of the carcinogenicity of tamoxifen, toremifene and their metabolites. , 1996, Mutation research.

[14]  K. Thomas,et al.  The occurrence of selected pharmaceuticals in wastewater effluent and surface waters of the lower Tyne catchment. , 2006, The Science of the total environment.

[15]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[16]  D. Grandjean,et al.  Trace determination of tamoxifen and 5-fluorouracil in hospital and urban wastewaters , 2006 .

[17]  Anthony Howell,et al.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. , 1992 .

[18]  K. Pritchard.  The Early Breast Cancer Trialists Collaborative Group (EBCTCG) Process: Is it Still Relevant in 2006? , 2006, Breast Care.

[19]  K. Thomas,et al.  The occurrence of selected human pharmaceutical compounds in UK estuaries. , 2004, Marine pollution bulletin.

[20]  Zijian Wang,et al.  Effects of binary mixtures of estrogen and antiestrogens on Japanese medaka (Oryzias latipes). , 2009, Aquatic toxicology.

[21]  J. Mellon.  The finasteride prostate cancer prevention trial (PCPT)--what have we learned? , 2005, European journal of cancer.

[22]  Catherine Legrand.  1687Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials : Early Breast Cancer Trialists' Collaborative Group (EBCTCG) , 2005 .

[23]  L. Wiest,et al.  Multi-residue analysis of steroids at sub-ng/L levels in surface and ground-waters using liquid chromatography coupled to tandem mass spectrometry. , 2008, Journal of chromatography. A.

[24]  S. Self,et al.  Ovarian tumors in a cohort of infertile women. , 1994, The New England journal of medicine.

[25]  J. Zhou,et al.  Simultaneous determination of various pharmaceutical compounds in water by solid-phase extraction-liquid chromatography-tandem mass spectrometry. , 2007, Journal of chromatography. A.

[26]  S. Teh,et al.  Androgen disruption of early development in Qurt strain medaka (Oryzias latipes). , 2007, Aquatic toxicology.

[27]  K. Fent,et al.  Ecotoxicology of human pharmaceuticals. , 2006, Aquatic toxicology.

[28]  T. Pasanen,et al.  Re: Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth. , 1999, Journal of the National Cancer Institute.